Summary Amgen has filed for approval the first of a new class of proteins to lower LDL cholesterol. These PCSK9 inhibitors are expected to see Amgen's evolocumab and Regeneron/Sanofi's alirocumab reach market within a year. Enough information has ... Seeking Alpha, 1 week ago
Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? - FiercePharma, 2 weeks ago
Early Hint At Cardiovascular Outcomes With Sanofis and Regenerons Rapidly Advancing Cholesterol Drug - Big News Network, 2 weeks ago
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions. Jason Meyer, a University of ...World Pharma News, 1 week ago Type of bad cholesterol might actually be good Medical News Today, 1 week ago Investigators make thought-provoking discovery about type of cholesterol believed to be "bad guy" News-Medical.Net, 2 weeks ago Oxidized LDL Might Not Be the "Bad Guy" In the Development of Plaque Inside Artery Walls, Research Suggests Infrosoft, 2 weeks ago
Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines...
Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency By a News Reporter-Staff News Editor at Clinical Trials Week Amgen (NASDAQ:AMGN) announced ...Pharmacy Choice, 4 days ago Amgen seeks marketing approval from EMA for LDL cholesterol-lowering medication, Evolocumab PharmaBiz, 2 weeks ago Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4 Traders, 2 weeks ago Amgen Submits BLA For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab Drugs.com, 2 weeks ago
A protein that increases levels of LDL (low-density lipoprotein) cholesterol, also referred to as "bad" cholesterol, in the bloodstream is associated with heart attacks, says a study. Levels of the protein PCSK9 were elevated in the blood of ...Siasat Daily, 2 weeks ago The Building Where Apple Will Unveil The iPhone 6 Could Fit A House, Or A Gym Yahoo! Malaysia, 2 weeks ago 7 Innocent Malaysian News Stories that are (OMG!!) SEDITIOUS!! Yahoo! Malaysia, 2 weeks ago PAC mahu 50% kutipan VEP diberi kepada rakyat Johor Yahoo! Malaysia, 2 weeks ago
CNBC | September 02, 2014 A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known ...NBCNews.com, 2 weeks ago PCSK9 and Other Novel Hypercholesterolemia Drugs Global Information Inc, 1 week ago
BARCELONA, SPAIN — Treatment with alirocumab (Sanofi/Regeneron Pharmaceuticals), an investigational proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in significant reductions in LDL cholesterol in various groups of ...Medscape, 2 weeks ago Regeneron anti-cholesterol drug effective in clinical trials Fairfield Business Journal, 2 weeks ago Regeneron and Sanofi announce positive results from hypercholesterolemia trials Individual.com, 1 week ago REGENERON PHARMACEUTICALS : and Sanofi Reports Positive Results from 4 Alirocumab Trials at ESC Congress 2014 4 Traders, 2 weeks ago
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction Amgen (NASDAQ: AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol ReductionUsing a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular ...Asian Hospital & Healthcare Management, 2 weeks ago
A type of cholesterol that has been thought to be bad due to increased risk of heart disease and other conditions could instead be a 'good guy', a new study conducted by researchers at University of Kentucky reveals. Jason Meyer, a University of Kentucky ...Med India, 2 weeks ago
For decades, clinicians have relied on cholesterol-based measures of LDL to predict and manage their patients risk for CVD. This practice has continued for historical reasons despite the emergence of new, real-world data suggesting that an ...Orthopedics Today, 1 week ago
Treatment goals to lower "bad" cholesterol or LDL cholesterol are less likely to be achieved by women with type 2 diabetes and high cholesterol than their male peers, despite access to cholesterol-lowering medication, a Canadian study finds. The results were ...Med India, 2 months ago Gender-Based Treatment Needed for Cardiovascular Risk Factors in Type 2 Diabetes Med India, 2 months ago Daily breakfast consumption lowered type 2 diabetes risk profile in children Orthopedics Today, 1 week ago Health Roundup: Obesity, Diabetes, Cardiac Risks MedPage Today, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!